FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study

Table 1 Patient characteristics of the overall population according to first-line chemotherapy, n (%)

Characteristics	FOLFIRINOX (n = 124)	FOLFOXIRI (n = 165)	P value
Demographic parameters
Age, median [IQR], yr	60.2 [53.0-65.9]	62.5 [54.6-67.5]	0.174
Missing	1	0
Gender			0.989
Male	73 (58.9)	97 (58.8)
Female	51 (41.1)	68 (41.2)
Familial history of cancer			0.195
No	32 (45.1)	89 (54.3)
Yes	39 (54.9)	75 (45.7)
Missing	53	1
Personal history of cancer			0.219
No	110 (90.2)	139 (85.3)
Yes	12 (9.8)	24 (14.7)
Missing	2	2
Pathological parameters
Stage at diagnosis			< 0.001
Localized	20 (16.1)	13 (7.9)
Locally advanced	18 (14.5)	60 (36.3)
Metastatic	86 (69.4)	92 (55.8)
Primary tumor site			0.022
Head	53 (43.1)	93 (56.7)
Body and/or tail	70 (56.9)	71 (43.3)
Missing	1	1
Histological grade			0.014
Well or moderately differentiated	45 (83.3)	39 (62.9)
Poorly differentiated or undifferentiated	9 (16.7)	23 (37.1)
Missing	70	103
Tumor extension
Stage at chemotherapy initiation			< 0.001
Locally advanced	14 (11.3)	60 (36.4)
Metastatic	110 (88.7)	105 (63.6)
Number of metastatic sites			< 0.001
0	14 (11.3)	60 (36.6)
1	69 (55.7)	74 (44.9)
≥ 2	41 (33.0)	31 (18.8)
Lymph node metastases			< 0.001
No	95 (76.6)	153 (92.7)
Yes	29 (23.4)	12 (7.3)
Liver metastases			< 0.001
No	37 (29.8)	84 (50.9)
Yes	87 (70.2)	81 (49.1)
Peritoneal metastases			0.124
No	109 (87.9)	134 (81.2)
Yes	15 (12.1)	31 (18.8)
Lung metastases			0.133
No	102 (82.3)	146 (88.5)
Yes	22 (17.7)	19 (11.5)
Other metastases			0.060
No	116 (93.6)	162 (98.2)
Yes	8 (6.4)	3 (1.8)
Clinical parameters
Performance status (WHO)			0.185
0	42 (35.0)	54 (32.7)
1	66 (55.0)	103 (62.4)
≥ 2	12 (10.0)	8 (4.9)
Missing	4	0
Body mass index, kg/m2	23.9 [20.8-27.4]	23.0 [20.8-25.6]	0.114
Missing	9	0
Pain			< 0.001
No	90 (73.8)	83 (50.9)
Yes	32 (26.2)	80 (49.1)
Missing	2	2
Jaundice			0.266
No	114 (93.4)	148 (89.7)
Yes	8 (6.6)	17 (10.3)
Missing	2	0
Ascites			1.000
No	117 (95.9)	157 (96.3)
Yes	5 (4.1)	6 (3.7)
Missing	2	2
Biological parameters
Albumin, median [IQR], g/L	39.1 [37.0-43.0]	35.0 [29.0-39.0]	< 0.001
Missing	48	80
Lymphocytes, median [IQR], mm3			0.408
< 1000	10 (15.9)	12 (11.4)
≥ 1000	53 (84.1)	93 (88.6)
Missing	19	102
Neutrophil-to-lymphocyte ratio, median [IQR]			0.103
< 5	82 (78.1)	42 (66.7)
≥ 5	23 (21.9)	21 (33.3)
Missing	19	102
CA19-9, median [IQR], UI/mL	885.0 [79.0-4756.0]	650.0 [138.0-5300.0]	0.669
Missing	3	34
Previous treatment
Primary tumor resection			0.277
Yes	18 (14.5)	17 (10.3)
No	106 (85.5)	148 (89.7)
Adjuvant chemotherapy			0.865
Yes	12 (9.7)	15 (9.1)
No	112 (90.3)	150 (90.9)
Median follow-up time (95%CI), mo	30.8 [23.0-NA]	61.4 [43.2-87.9]

χ² tests or Fisher’s exact tests were used to compare proportions, and Wilcoxon tests were used to compare continuous variables between the FOLFIRINOX and FOLFOXIRI groups. All statistical tests were two-sided. CA19-9: Carbohydrate Antigen 19-9; IQR: Interquartile range; WHO: World Health Organization.